Why 2027 could be Europe's year to shine in biotech funding
At Fierce Biotech's London event, industry experts debated the future of European biopharma investment. Sofinnova Partners chairperson Antoine Papiernik predicted Europe's time to shine is coming, backed by recent massive funding rounds and strong AI talent. However, panelists noted that Europe still faces a capital deployment problem and heavily relies on the U.S. Nasdaq for IPOs.
During the opening panel at Fierce Biotech's London Life Sciences Week, industry leaders discussed the shifting landscape of biopharma funding. Antoine Papiernik, chairperson of Sofinnova Partners, argued that all the ingredients for success are aligning in Europe, just a day after his firm closed an $815 million fund targeting clinical-stage companies. Papiernik also highlighted China's role as a powerhouse for biopharma innovation, suggesting Europe has a unique opportunity to leverage those advancements.
Despite these positive signs, Søren Møller of Novo Holdings pointed out that Europe suffers from a capital problem rather than an innovation shortage, noting that local funds are hesitant to take on high investment risks. Papiernik added that the U.S. Nasdaq remains the only viable IPO market for European biotechs, forcing non-U.S. companies to build global strategies early just to compete.
Meanwhile, the ecosystem received another boost as Flagship Pioneering announced it chose London for its first international outpost. Lena Afeyan cited the region's strong AI talent and data focus as key drivers, predicting a surge in AI-driven biotech investments moving forward.
View selection rationale
Importance 53/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- Fierce Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.